Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FDD73
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,379
Award facts
- Contract value 100% obligated
- $12,379.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,379.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The award, issued on October 22, 2025, with an ultimate completion date of November 13, 2025, was made without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group serves as a critical supplier within the Department of Defense pharmaceutical supply chain, distributing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals to military healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract that positions the company as a regional prime vendor contractor supporting DoD medical supply needs worldwide. The underlying PPV-G GEN V acquisition strategy represents a $30.3 billion government-wide pharmaceutical supply initiative structured with a 30-month base period and three 30-month option periods extending through December 31, 2036. XOLAIR, a biologic immunosuppressant agent, aligns with DMS Pharmaceutical Group's established portfolio of specialty pharmaceuticals and demonstrates the contractor's capability to fulfill diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FDD73?
SPE2DB26FDD73 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 22, 2025.
How much is contract SPE2DB26FDD73 worth?
The government has obligated $12,379 on SPE2DB26FDD73.
Is contract SPE2DB26FDD73 an order under another contract?
Yes. SPE2DB26FDD73 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB26FDD73 competed?
The extent of competition for SPE2DB26FDD73 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award